Show simple item record

dc.contributor.authorCohen, Andrew N
dc.contributor.authorKessel, Bruce
dc.description.abstractLarge-scale testing for SARS-CoV-2 by the reverse transcription polymerase chain reaction is a key part of the response to the COVID-19 pandemic, but little attention has been paid to the potential frequency and impacts of false positive results. In the absence of data on the clinical specificity of SARS-CoV-2 assays, we estimate a conservative false positive rate from external quality assessments of similar viral assays, and show that this rate may have large impacts on the reliability of positive test results. This has clinical and case management implications, affects an array of epidemiological statistics, and should inform the scale of testing and the allocation of testing resources. Measures to raise awareness of false positives, reduce their frequency, and mitigate their effects should be considered.en_US
dc.subjectInfectious Diseasesen_US
dc.subjectFalse Positive Reactionsen_US
dc.subjectPolymerase Chain Reactionen_US
dc.titleFalse positives in reverse transcription PCR testing for SARS-CoV-2en_US
eihealth.countryGlobal (WHO/OMS)en_US
eihealth.categoryVirus: natural history, transmission and diagnosticsen_US
eihealth.typePublished Articleen_US
eihealth.maincategorySlow Spread / Reducir la Dispersiónen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record